Tenofovir Treatment Has Lower Risk of Hepatocellular....pdf (475.28 kB)

Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis

Download (475.28 kB)
journal contribution
posted on 03.08.2021, 15:29 by Hairong Liu, Yu Shi, John HaydenJohn Hayden, Paul M Ryan, Jamal Rahmani, Guangsheng Yu

Purpose: Tenofovir (TDF) and entecavir (ETV) are both equally recommended as first-line treatments for patients with chronic hepatitis B (CHB). They have comparable efficacy in virologic response, but their effect on the development of hepatocellular carcinoma (HCC) in CHB is controversial. Therefore, we aimed to compare TDF and ETV evaluating the risk of HCC development in CHB patients.

Methods: A systematic literature search was conducted up to November 2019 in MEDLINE/PubMed, SCOPUS, and Web of Science databases without language and time restrictions. DerSimonian and Laird random-effects models were used to estimate combined hazard ratios (HRs) and 95% CIs.

Results: Seven studies containing 35,785 participants were included in this systematic review and meta-analysis. The pooled HR (95% CI) of HCC in the patients who used TDF versus patients who used ETV was 0.75 (0.56-0.96). There was no significant heterogeneity detected among the included studies results (I2 = 47.5%). There was no significant publication bias detected among the included studies (Begg's p = 0.88 and Egger's regression test p = 0.96).

Conclusions: Evidence to date suggests that TDF treatment is associated with significantly fewer cases of HCC when compared to ETV.

Funding

Shandong Provincial Natural Science Foundation [grant numbers ZR2014HQ019]

History

Comments

The original article is available at https://www.karger.com

Published Citation

Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: A systematic review and meta-analysis. Liver Cancer. 2020;9(4):468-476

Publication Date

5 May 2020

PubMed ID

32999872

Department/Unit

  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Population Health and Health Services
  • Neurological and Psychiatric Disorders
  • Chemistry and Pharmaceutical Sciences
  • Health Professions Education

Publisher

S. Karger

Version

  • Published Version (Version of Record)